South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Tolerion is raising $39,999,993.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, John Donovan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Tolerion

Tolerion is a clinical-stage biopharmaceutical company with a product portfolio built around our novel antigen-specific immune tolerance induction platform. Our first three named product candidates, one in late stage clinical trials, address autoimmune disorders with candidates invented with our proprietary platform. Our fourth program, a monoclonal antibody for treatment of ALS, inhibits a novel integrin discovered by Larry Steinman and benefits from his lifetime of work in integrin biology, including his role in the discovery and development of integrin inhibitor, Tysabri.

To learn more about Tolerion, visit http://tolerion.bio/

Contact:
John Donovan, Chief Executive Officer
415-795-5800
https://www.linkedin.com/in/john-donovan-1605b677/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved